Advagene Biopharma Co. Ltd.
Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. It engages in the development of nasal spray influenza vaccine; respiratory allergy treatment vaccine, including rhinitis and asthma; COVID-19 immunotherapy; and other vaccines. The company was founded in 2006 and is based in Taipei, Taiwan.
Advagene Biopharma Co. Ltd. (6709) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: 0.000x
Based on the latest financial reports, Advagene Biopharma Co. Ltd. (6709) has a cash flow conversion efficiency ratio of 0.000x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-13.44K) by net assets (NT$108.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Advagene Biopharma Co. Ltd. - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Advagene Biopharma Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Advagene Biopharma Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Advagene Biopharma Co. Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Auric Mining Ltd
AU:AWJ
|
0.143x |
|
Budapesti Ingatlan Hasznositasi es Fejlesztesi Nyrt.
BUD:BIF
|
0.017x |
|
Jindal Poly Investment and Finance Company Limited
NSE:JPOLYINVST
|
0.004x |
|
NEOOTO Co. Ltd
KQ:212560
|
0.055x |
|
Live Verdure Ltd
AU:LV1
|
-0.448x |
|
Molinos Juan Semino SA
BA:SEMI
|
0.001x |
|
LTR Pharma Ltd
AU:LTP
|
-0.076x |
|
Spanish Mountain Gold Ltd.
OTCQB:SPAUF
|
0.001x |
Annual Cash Flow Conversion Efficiency for Advagene Biopharma Co. Ltd. (2017–2024)
The table below shows the annual cash flow conversion efficiency of Advagene Biopharma Co. Ltd. from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$220.54 Million | NT$-70.64 Million | -0.320x | +42.30% |
| 2023-12-31 | NT$139.96 Million | NT$-77.70 Million | -0.555x | +33.11% |
| 2022-12-31 | NT$131.76 Million | NT$-109.35 Million | -0.830x | -208.32% |
| 2021-12-31 | NT$249.57 Million | NT$-67.18 Million | -0.269x | -160.85% |
| 2020-12-31 | NT$299.32 Million | NT$-30.89 Million | -0.103x | -78356.88% |
| 2019-12-31 | NT$271.37 Million | NT$-35.69K | 0.000x | +99.88% |
| 2018-12-31 | NT$346.89 Million | NT$-39.46 Million | -0.114x | +86.27% |
| 2017-12-31 | NT$213.72 Million | NT$-177.05 Million | -0.828x | -- |